The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis. There were 151 participants in PRIME (dupilumab, n = 75) from 58 study sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results